Australia's Monash slips; Macquarie positive on IVF industry, raises forecast

Monash IVF

29/11/2023 24:51

** Macquarie sees Australia's Monash IVF  MVF.AX  benefiting
from a strong patient pipeline and recent acquisitions 
    ** Brokerage says co's 1H24 expected underlying NPAT of
A$14.5 mln - A$15 mln ($9.64 mln-$9.98 mln) is about 5% ahead of
brokerage's consensus
    ** We increase our 1H24 underlying NPAT forecasts to A$14.75
million from A$14 million- Macquarie 
    ** Brokerage increases target price by 7% to A$1.50 for co,
retains "outperform" rating  
    ** Macquarie continues to see structural tailwinds for the
IVF industry, with MVF well-placed for ongoing share gains 
        ** Stock down 2.3% at A$1.250
    ** Monash stock up 34% this year, as of last close

    ($1 = 1.5038 Australian dollars)

 (Reporting by Nausheen Thusoo in Bengaluru)
 ((Nausheen.Thusoo@thomsonreuters.com;))